Serina Therapeutics (NYSEAMERICAN:SER) Trading 6.8% Higher – Time to Buy?

Serina Therapeutics, Inc. (NYSEAMERICAN:SER)’s stock price rose 6.8% during mid-day trading on Tuesday . The stock traded as high as $2.10 and last traded at $2.04. Approximately 141,701 shares traded hands during mid-day trading, an increase of 1% from the average daily volume of 139,816 shares. The stock had previously closed at $1.91.

Serina Therapeutics Trading Up 6.8%

The company has a market capitalization of $30.60 million, a price-to-earnings ratio of -1.02 and a beta of 1.15. The firm’s 50 day moving average is $1.86. The company has a quick ratio of 4.18, a current ratio of 4.18 and a debt-to-equity ratio of 0.24.

Serina Therapeutics (NYSEAMERICAN:SER) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.58) earnings per share (EPS) for the quarter.

Insider Activity

In related news, insider Randall Moreadith sold 39,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $2.50, for a total transaction of $97,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders purchased 32,283 shares of company stock worth $55,577. 17.70% of the stock is currently owned by company insiders.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.